- Home
- GITS vs CMMB Comparison
GITS vs CMMB Comparison
Compare GITS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | CMMB |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | South Korea | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 9.1M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GITS | CMMB |
|---|---|---|
| Price | $2.45 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | ★ 151.8K | 80.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.87 |
| 52 Week High | $7.09 | $3.86 |
Technical Indicators
Market Signals| Indicator | GITS | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 57.88 |
| Support Level | $2.13 | $1.48 |
| Resistance Level | $3.28 | $2.80 |
| Average True Range (ATR) | 0.51 | 0.17 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 32.88 | 79.11 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.